30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Sagimet Biosciences Inc (SGMT)

Track

The most recent insider trading activity occurred on February 10, 2026, with multiple executives, including the President & CEO, Chief Medical Officer, and Chief Financial Officer, selling shares. Prior to this, planned and proposed sales were noted in November 2025. The last reported buy transaction was by the President & CEO on March 26, 2024.
Stock chart
Ticker: SGMT Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Chauche Thierry
Chief Financial Officer
1 sale — total 7,033 USD
Sale 10 Feb 2026
Value US$4,316,895.93 | Price 476.82 | Shares 93,955
Sale 10 Feb 2026
Value US$4,526,421.27 | Price 382.91 | Shares 38,054
Sale 10 Feb 2026
Value US$14,054.44 | Price 5.36 | Shares 2,622
Sale 10 Feb 2026
Value US$19,511.13 | Price 5.36 | Shares 3,640
Planned sale 20 Nov 2025
Value US$289,979.01 | Price 7.69 | Shares 37,688
Proposed sale 20 Nov 2025
Value US$295,850.80 | Price 7.85 | Shares 37,688
Sale 21 Jul 2025
Value US$98,470.99 | Price 9.13 | Shares 10,780
Sale 21 Jul 2025
Value US$75,607.08 | Price 9.13 | Shares 8,277
Sale 21 Jul 2025
Value US$598,115.34 | Price 9.13 | Shares 65,478
Planned sale 23 Jul 2024
Value US$74,829.83 | Price 3.17 | Shares 23,625
Proposed sale 23 Jul 2024
Value US$73,001.25 | Price 3.09 | Shares 23,625
Sale 19 Jul 2024
Value US$33,830.13 | Price 3.10 | Shares 10,914
Sale 19 Jul 2024
Value US$25,910.04 | Price 3.10 | Shares 8,357
Sale 19 Jul 2024
Value US$43,604.86 | Price 3.10 | Shares 14,062
Buy 26 Mar 2024
Value US$63,730.70 | Price 5.27 | Shares 12,100
Buy 7 Dec 2023
Value US$6,560.00 | Price 4.10 | Shares 1,600
Buy 16 Nov 2023
Value US$1,386.50 | Price 2.35 | Shares 590
Buy 18 Jul 2023
Value US$750,000.00 | Price 16.00 | Shares 46,875
Buy 18 Jul 2023
Value US$480,000.00 | Price 16.00 | Shares 30,000
Sale 18 Jul 2023
Value US$10,592.00 | Price 16.00 | Shares 662
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-12 2026-02-10 S Sale
1.2
Chauche Thierry

Chief Financial Officer

Officer
93,955 -41.7%
476.82
US$4,316,896 		93,955 -41.7% 476.82 US$4,316,896
2026-02-12 2026-02-10 S Sale
3.3
Happel David

President & CEO

Executive Director
38,054 -23.4%
382.91
US$4,526,421 		38,054 -23.4% 382.91 US$4,526,421
2026-02-12 2026-02-10 S Sale
3.0
Rozek Elizabeth

Chief Legal & Admin. Officer

Officer
36,203 -10.2%
259.04
US$73,467 		36,203 -10.2% 259.04 US$73,467
2026-02-12 2026-02-10 S Sale
2.9
Martins Eduardo Bruno

Chief Medical Officer

Officer
3,640 -3.4%
5.36
US$19,511 		3,640 -3.4% 5.36 US$19,511
2025-11-21 2025-11-20 PlS Planned sale
1.4
Kemble George

Executive Chairman

Executive Director
37,688 -31.8%
7.69
US$289,979 		37,688 -31.8% 7.69 US$289,979
2025-11-20 2025-11-20 PrS Proposed sale
1.4
GEORGE KEMBLE

Director; Officer

Executive Director
37,688
7.85
US$295,851 		37,688 7.85 US$295,851
2025-07-23 2025-07-21 S Sale
3.0
Rozek Elizabeth

General Counsel and CCO

Officer
10,780 -5.5%
9.13
US$98,471 		10,780 -5.5% 9.13 US$98,471
2025-07-23 2025-07-21 S Sale
2.9
Martins Eduardo Bruno

Chief Medical Officer

Officer
8,277 -7.2%
9.13
US$75,607 		8,277 -7.2% 9.13 US$75,607
2025-07-23 2025-07-21 S Sale
3.3
Happel David

President & CEO

Executive Director
65,478 -8.7%
9.13
US$598,115 		65,478 -8.7% 9.13 US$598,115
2024-07-25 2024-07-23 PlS Planned sale
1.4
Kemble George

Executive Chairman

Executive Director
23,625 -16.6%
3.17
US$74,830 		23,625 -16.6% 3.17 US$74,830
2024-07-23 2024-07-23 PrS Proposed sale
1.4
GEORGE KEMBLE

Director; Officer

Executive Director
23,625
3.09
US$73,001 		23,625 3.09 US$73,001
2024-07-23 2024-07-19 S Sale
3.0
Rozek Elizabeth

General Counsel and CCO

Officer
10,914 -6.4%
3.10
US$33,830 		10,914 -6.4% 3.10 US$33,830
2024-07-23 2024-07-19 S Sale
2.9
Martins Eduardo Bruno

Chief Medical Officer

Officer
8,357 -9.3%
3.10
US$25,910 		8,357 -9.3% 3.10 US$25,910
2024-07-23 2024-07-19 S Sale
1.4
Kemble George

Executive Chairman

Executive Director
14,062 -9.0%
3.10
US$43,605 		14,062 -9.0% 3.10 US$43,605
2024-03-28 2024-03-26 B Purchase
3.3
Happel David

President & CEO

Executive Director
12,100 +1.9%
5.27
US$63,731 		12,100 +1.9% 5.27 US$63,731
2023-12-08 2023-12-07 B Purchase
3.3
Happel David

President & CEO

Executive Director
1,600 +0.3%
4.10
US$6,560 		1,600 +0.3% 4.10 US$6,560
2023-11-20 2023-11-16 B Purchase
3.3
Happel David

President & CEO

Executive Director
590 +inf%
2.35
US$1,386 		590 +inf% 2.35 US$1,386
2023-07-20 2023-07-18 B Purchase
3.7
SEIDENBERG BETH C
Non-Executive Director
46,875 +inf%
16.00
US$750,000 		46,875 +inf% 16.00 US$750,000
2023-07-20 2023-07-18 B Purchase
2.5
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
30,000 +0.8%
16.00
US$480,000 		30,000 +0.8% 16.00 US$480,000
2023-07-20 2023-07-18 S Sale
2.5
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
662 -0.0%
16.00
US$10,592 		662 -0.0% 16.00 US$10,592
Explore more

More insider trading research around Sagimet Biosciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America